DS
DSGN icon

David Shaw’s Design Therapeutics DSGN Stock Holding History

David Shaw’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.83M Sell
195,645
-274,625
-58% -$3.42M ﹤0.01% 2908
2026
Q1 		$5M Buy
470,270
+31,376
+7% +$317K ﹤0.01% 2175
2025
Q4 		$4.12M Buy
438,894
+65,618
+18% +$514K ﹤0.01% 2469
2025
Q3 		$2.81M Sell
373,276
-17,372
-4% -$87K ﹤0.01% 2714
2025
Q2 		$1.32M Sell
390,648
-4,603
-1% -$17.2K ﹤0.01% 3044
2025
Q1 		$1.53M Sell
395,251
-117,079
-23% -$559K ﹤0.01% 2805
2024
Q4 		$3.16M Sell
512,330
-70,528
-12% -$408K ﹤0.01% 2355
2024
Q3 		$3.14M Buy
582,858
+47,074
+9% +$221K ﹤0.01% 2343
2024
Q2 		$1.79M Buy
535,784
+89,594
+20% +$349K ﹤0.01% 2745
2024
Q1 		$1.8M Buy
446,190
+155,562
+54% +$415K ﹤0.01% 2717
2023
Q4 		$770K Buy
290,628
+278,888
+2,376% +$639K ﹤0.01% 3303
2023
Q3 		$27.7K Sell
11,740
-123,540
-91% -$576K ﹤0.01% 3957
2023
Q2 		$852K Buy
135,280
+23,982
+22% +$147K ﹤0.01% 3174
2023
Q1 		$642K Buy
+111,298
New +$832K ﹤0.01% 3429

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's DSGN Position: Q2 2026 in Review

David Shaw reduced its Design Therapeutics (DSGN) stake by 58% in Q2 2026, selling an estimated $3.42M and leaving 195,645 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

David Shaw first reported a position in DSGN in Q1 2023 and has held it in 14 quarters since. The position peaked at $5M in Q1 2026. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • David Shaw held 195,645 shares of Design Therapeutics worth $2.83M as of Q2 2026.
  • David Shaw sold 274,625 Design Therapeutics shares in Q2 2026, an estimated $3.42M.
  • Design Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2908 holding.
  • David Shaw first reported a position in Design Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • David Shaw's Design Therapeutics position peaked at $5M in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.